Skip to main content

Apyx Medical Corp

corporate_fare Company Profile

Apyx Medical Corp

APYX·NASDAQ·Life Sciences·CIK 0000719135

The company is a surgical aesthetics company that develops innovative products for cosmetic and hospital surgical markets. Its key products include the Helium Plasma Platform Technology products, Renuvion and J-Plasma, and the AYON Body Contouring System. Renuvion and J-Plasma provide surgeons with controlled heat for tissue. AYON is an FDA-cleared, surgeon-designed body contouring system that integrates fat removal, closed-loop contouring, and Renuvion's tissue contraction and electrosurgical capabilities. The company also uses its expertise in unique waveforms through OEM agreements with other medical device manufacturers. On May 13, 2025, the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AYON. It completed a soft launch of AYON and commenced its commercial launch in September 2025. AYON is designed as an all-in-one system for comprehensive body contouring, integrating advanced modalities to perform multiple functions. These functions include infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation for excess tissue removal, volume enhancement capabilities, and Renuvion treatment for loose and lax skin. On October 13, 2025, the company submitted a 510(k) premarket notification to the FDA for AYON's label expansion to include power liposuction.

Apyx Medical Corp (NASDAQ:APYX) is a publicly traded company in the Life Sciences sector. Wiseek monitors APYX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Apyx Medical Study Shows Up to 81.8% Cellulite Improvement with Combined Avéli and Renuvion
  • Apyx Medical Announces Positive Clinical Data for Renuvion in Cellulite and Skin Laxity Treatment
  • Avéli® and Renuvion® Combo Shows Significant Cellulite, Skin Laxity Improvement in New Study
  • Apyx Medical Announces Positive Clinical Study for Renuvion in Body Contouring
  • Apyx Medical receives expanded FDA clearance for AYON Body Contouring System to include power liposuction

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$52.84M
Net Income
-$11.21M
Op. Cash Flow
-$8M
Free Cash Flow
-$9.12M
Gross Profit
$33.04M
Operating Income
-$6.45M
Cash & Equivalents
$31.74M
Total Debt
$34.85M
Debt / Equity
2.40×
Net Margin
-21.2%
Shares Outstanding
41.79M sh
Source: 10-K · filed 2026-03-10 · accession 0001437749-26-007471
Browse all tickers starting with A →
$4.69
52-week range · as of 2026-05-21 $1.38 – $4.5
Market cap
$196.39M
Volume
160.9K (0.7× avg)
3-mo avg 234.8K
Live data · 2026-06-14 05:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed APYX - Latest Insights

APYX
May 21, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $4.69 info
Change: +$0.440 (+10%) info
Market Cap: $196.389M info
APYX
May 21, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $4.69 info
Change: +$0.440 (+10%) info
Market Cap: $196.389M info
APYX
May 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $4.69 info
Change: +$0.900 (+24%) info
Market Cap: $196.389M info
APYX
May 14, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $4.69 info
Change: +$0.850 (+22%) info
Market Cap: $196.389M info
APYX
May 11, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.78
Real-time Price: $4.69 info
Change: +$0.910 (+24%) info
Market Cap: $196.389M info
APYX
May 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.78
Real-time Price: $4.69 info
Change: +$0.910 (+24%) info
Market Cap: $196.389M info
APYX
May 07, 2026, 4:55 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $4.69 info
Change: +$1.31 (+39%) info
Market Cap: $196.389M info
APYX
May 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.34
Real-time Price: $4.69 info
Change: +$1.35 (+40%) info
Market Cap: $196.389M info
APYX
Mar 10, 2026, 1:15 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.53
Real-time Price: $4.69 info
Change: +$1.16 (+33%) info
Market Cap: $196.389M info
APYX
Mar 10, 2026, 1:11 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $3.57
Real-time Price: $4.69 info
Change: +$1.13 (+32%) info
Market Cap: $196.389M info
APYX
Mar 10, 2026, 7:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.60
Real-time Price: $4.69 info
Change: +$1.09 (+30%) info
Market Cap: $196.389M info
APYX
Mar 10, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $4.69 info
Change: +$1.09 (+30%) info
Market Cap: $196.389M info
APYX
Mar 06, 2026, 7:32 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $4.69 info
Change: +$1.43 (+44%) info
Market Cap: $196.389M info
APYX
Jan 12, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.55
Real-time Price: $4.69 info
Change: +$1.14 (+32%) info
Market Cap: $196.389M info